The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations. Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to its pharmacological characteristics. The hypothesis of this study is that Dexmedetomidine would allow effective and safe light sedation in patients with respiratory failure in palliative situations suffering from Covid-19 infection.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
University Hospital
Limoges, France
Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.
Number of days of mild to moderate sedation induced by dexmedetomidine until death or change of molecule.
Time frame: Day 30
Overall survival of patients on Dexmedetomidine
Overall survival time in days from inclusion.
Time frame: Day 30
Daily analgesic effect of Dexmedetomidine
The daily effectiveness of Dexmedetomidine on pain assessed by the NCS-R scale (Nociception Coma Scale) : the score is between 0 and 9.
Time frame: Day 30
Other sedative pharmacological agents
Number of the various sedative molecules used in the subjects of the study in addition to Dexmedetomidine.
Time frame: Day 30
Average dosage required for Dexmedetomidine to achieve mild to moderate sedation
Daily dosage measurement in ug / kg / h of Dexmedetomidine necessary to obtain light to moderate sedation
Time frame: Day 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.